Molecular Partners signs US$420 million contract on antibody mimetic with Allergan


Zurich/Schlieren – Swiss Molecular Partners AG has bagged a US$45 million upfront payment and the option for additional US$345 million milestones from Allergan Inc for an exclusive licence of its Phase 2 anti-VEGF antibody mimetic MP0112 for the treatment of retinal diseases. In addition, Molecular Partners could receive tiered double-digit royalties on any future sales of MP0112. Allergan gains exclusive global rights for MP0112 for ophthalmic indications of the so-called DARPin molecule. DARPins are temperature stable, 14KDa scaffolds of 2-4 domains of the ankyrin protein motif that mimic the antigen binding capacities of antibody drugs while offering advantages of smaller molecules. Data on MP0112 from two separate phase I/IIa trials in wet age-related macular degeneration (wetAMD) and diabetic macular edema (DME) suggest that MP0112 is well-tolerated and has a potentially long lasting effect on vision gain after one single injection. In the studies, for most patients in the cohorts treated with the higher dose of the investigational compound, the potential beneficial effect on visual acuity lasted for approximately 16 weeks.



Zurich – Overexpression of two microRNAs trigger development of insulin resistance, a hallmark of type II diabetes which affects about 20% of the elderly (aged 55-74) in the western world. In Nature, a research team headed by...



Basel/Würzburg – Scientists from Swiss Novartis AG have cracked the mechanism that leads to permanent activation of the immune system in course of atherosclerosis and have targeted an antibody against it in mice and humans (JCI,...



Basel - Scientists at Roche Holding AG's subsidiary Genentech have found a way to get antibodies across the blood-brain barrier that block the enzyme beta-secretase 1 which is believed to prevent formation of Alzheimer's plaques....



Allschwil – Swiss biotech firm Actelion Pharma has reached the primary endpoint of preventing allergic rhinitis symptoms in patients challenged with Mountain Cedar pollen in a proof-of-concept study with its oral CRTH2...



Basel – Swiss drugmaker Roche has filed for MAA in Europe and the U.S. for vemurafenib (RG7204, PLX4032 , RO5185426) in patients with malignant melanoma who carry the common B-Raf V600E mutation. The oral B-RAF blocker interrupts...



Basel – Novartis COPD drug NVA237 (glycopyrronium bromide) has met the primary endpoint of superior bronchodilation to placebo at 12 weeks in a Phase III study with 800 participants, according to the Swiss drug giant’s...



Zurich – Researchers under Prof Dario Neri from ETH Zurich have presented a new approach that cured squamous cell carcinoma in two mouse models (Br. J Cancer, doi: 10.1038/bjc.12.04.11). The founder of the biotech firm Philogen,...



Zurich – Swiss Novartis AG has discontinued a Phase III head-to-head comparison of Tasigna (nilotinib) with the company’s US-$4 million blockbuster Glivec (imatinib) as first-line treatment of gastrointestinal stromal tumours...

Displaying results 41 to 50 out of 276

< Previous 41-50 Next >

© 2007-2015 BIOCOM



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week


Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...


All Events



BioVaria 2015

Stock list

All quotes


  • CYTOS1.32 CHF30.69%
  • WILEX5.08 EUR17.32%
  • SYNGENTA339.90 CHF8.11%


  • THERAMETRICS0.07 CHF-12.50%
  • MEDIGENE10.26 EUR-6.39%
  • MOLOGEN4.85 EUR-1.82%


  • 4SC5.20 EUR306.2%
  • WILEX5.08 EUR77.6%
  • PAION2.86 EUR21.7%


  • BIOTEST71.20 EUR-26.7%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.26 EUR-16.8%


  • SANTHERA98.00 CHF2362.3%
  • CYTOS1.32 CHF500.0%
  • WILEX5.08 EUR483.9%


  • MOLOGEN4.85 EUR-56.0%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.30 EUR-27.7%

No liability assumed, Date: 04.05.2015

Current issue

All issues